Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. - Wikidata - wikimedia - TriplyDB

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.

http://www.wikidata.org/entity/Q35079536

about

Dual modulation of MCL-1 and mTOR determines the response to sunitinib.The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma Establishment of a large panel of patient-derived preclinical models of human renal cell carcinoma LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma.Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.Strategies to overcome therapeutic resistance in renal cell carcinoma.Can individualized sunitinib dose and schedule changes optimize outcomes for kidney cancer patients?Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity.From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib.The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy.Experimental imaging in orthotopic renal cell carcinoma xenograft models: comparative evaluation of high-resolution 3D ultrasonography, in-vivo micro-CT and 9.4T MRI.Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.Immunotherapeutic Targeting of Tumor-Associated Blood Vessels.The epigenetic landscape of clear-cell renal cell carcinoma.Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma.Renal cancer: new models and approach for personalizing therapy Sunitinib rechallenge with dose escalation in progressive metastatic renal cell carcinoma: A case report and literature review

P2860

Q37544978-B133A453-7248-4DE9-8BD8-CCC7C33CC8C7 Q37644821-50AAED21-C0EE-4CB5-9408-5A952BAD36F6 Q37644869-9920B66A-F0D9-4608-B40A-30129EDF7BBF Q38710038-64241432-180B-4AC4-8811-FA64B322ABC4 Q39008859-6D701AA0-D5D4-494F-B42C-CD76061296A8 Q39089402-1887B070-6168-4ED9-9F13-5AD90B2D591F Q39092944-EFBDCBF7-BD99-4740-B020-23FC1819B3C9 Q42333847-7D43E33D-968F-4434-9148-BE4CDD5A0710 Q42700492-7F34A76A-E9EC-4D4C-A50A-E91D5F7F22B7 Q44456046-6F6FAF53-ABCE-49DF-B888-7C865218A2BF Q47148716-151287B3-B317-4B50-BF11-33DBEB1CD8A7 Q47252459-3089EB4E-291A-465C-97B1-6E47414A131D Q47600932-4A8E4CE1-8603-4B3A-822B-4DBEF8D714E7 Q49592831-B9410053-FCA8-43D0-9FA5-8DAF1459A4F7 Q51091490-C672547D-5341-4192-BD2D-2CD770935997 Q55066009-A6D7AB99-99A8-49D2-A762-7711009A7E86 Q57160714-60235B9A-4F9C-4085-A203-E7C568036A58 Q58802067-90B670F4-5272-4C0F-91E3-98CAA853409E

P2860

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.

http://www.wikidata.org/entity/Q35079536

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Sunitinib dose escalation over ...... with epigenetic modifications.

@ast

Sunitinib dose escalation over ...... with epigenetic modifications.

@en

type

label

Sunitinib dose escalation over ...... with epigenetic modifications.

@ast

Sunitinib dose escalation over ...... with epigenetic modifications.

@en

prefLabel

Sunitinib dose escalation over ...... with epigenetic modifications.

@ast

Sunitinib dose escalation over ...... with epigenetic modifications.

@en

P1433

Q35079536-DDF6357B-6E63-49CD-8A91-98DB14A4B0BB

P1476

Q35079536-7DA68659-799D-4EE4-A996-FF479B99236B

P2093

Q35079536-33D074DB-E611-4346-9BD2-BE1079BAC7CC

Q35079536-477BEFF7-89EA-4DEC-9964-D56F7DBB51BE

Q35079536-494596E8-CDE9-4D29-B05B-0C1B02FBB18F

Q35079536-5B2B1312-3859-4358-B000-E8C29987E012

Q35079536-70297637-35E8-4940-9104-6DBD8AFB5649

Q35079536-7912922B-51BE-4AC7-8F2E-F73F8EB34459

Q35079536-84BE3958-19DE-4B63-B9B8-66D6C84B7355

Q35079536-9A4897CA-318C-48E2-ABAD-DA04242D7E8B

Q35079536-A269BE0D-EDB1-405A-A3BE-E655598EA817

Q35079536-A3D4BA65-04A9-49F4-B42F-EA16FD120968

P2860

Q35079536-0EB04671-4FFB-40AB-B010-C9A0380D0F00

Q35079536-14429878-1C12-481F-AF43-F44535A5A30C

Q35079536-1B0FD10D-E931-4D4B-B2F3-2478B2B3CF30

Q35079536-275FDEE0-727F-4D68-BFFD-74295F3F3EC6

Q35079536-2796AFC1-F7F7-4EDD-A4A4-8A97AF76673C

Q35079536-34CA320F-E533-48D4-B335-3CE69B218E27

Q35079536-3E3FDB6A-336E-4FF0-892D-92BEEC43CED1

Q35079536-4A1DF0A5-E0F5-4C65-A062-58BFFA1ED089

Q35079536-4CFE7429-F480-45F5-A4F6-DCCC97D93F54

Q35079536-51903ADB-5593-4802-9A2A-A8F7ECB58D5F

P304

Q35079536-F0F6411D-8F69-416F-B9D1-0D2DEAFD96FD

P31

Q35079536-5A720753-AA62-42E9-AC04-D0A2A04FF09A

P356

Q35079536-67B5B496-A24E-4080-85F2-0522DFDCE162

P433

Q35079536-DEF5AD9D-48E3-4EF2-AA9A-C1EAD527E774

P478

Q35079536-7DB5BD7B-B44D-4D58-984C-2CF38E31DC37

P577

Q35079536-134D228D-DD8C-4060-B949-13EF6F387F9E

P5875

Q35079536-06B53544-EB15-4157-B4C6-F182ECF38528

P698

Q35079536-DBD73837-81B9-4AD0-983F-E0A9234E57E2

P932

Q35079536-9BAE6943-F82B-4643-B338-A0D54EE3AA19

P356

1535-7163.MCT-14-0208

P1433

Molecular Cancer Therapeutics

P1476

Sunitinib dose escalation over ...... with epigenetic modifications.

@en

P2093

Ashley Orillion

http://www.w3.org/2001/XMLSchema#string

Dylan Conroy

http://www.w3.org/2001/XMLSchema#string

Eric Ciamporcero

http://www.w3.org/2001/XMLSchema#string

Georg A Bjarnason

http://www.w3.org/2001/XMLSchema#string

Gerald Fetterly

http://www.w3.org/2001/XMLSchema#string

Jonathan Bard

http://www.w3.org/2001/XMLSchema#string

Joshua Prey

http://www.w3.org/2001/XMLSchema#string

Kiersten Marie Miles

http://www.w3.org/2001/XMLSchema#string

Li Shen

http://www.w3.org/2001/XMLSchema#string

Maria Tsompana

http://www.w3.org/2001/XMLSchema#string

P2860

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies

Comprehensive molecular characterization of clear cell renal cell carcinoma.

Cancer statistics, 2013

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.

Long noncoding RNA-EBIC promotes tumor cell invasion by binding to EZH2 and repressing E-cadherin in cervical cancer

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

Regulation of tumor angiogenesis by EZH2.

Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.

P304

513-522

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-14-0208

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269771039

http://www.w3.org/2001/XMLSchema#string

P698

25519701

http://www.w3.org/2001/XMLSchema#string

P932

4326587

http://www.w3.org/2001/XMLSchema#string